When it comes to live vaccines and the medication Cosentyx (secukinumab), there are recommendations to ensure the safety and efficacy of the vaccines. However, it is essential to consult with a healthcare professional for personalized advice.
Live vaccines contain weakened forms of the virus or bacteria they protect against. Cosentyx is a medication used to treat various conditions, such as plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis [1]. Cosentyx belongs to a class of drugs called monoclonal antibodies, which can affect the immune system's response to vaccines [2].
According to the available information, the recommended timeline for live vaccines and Cosentyx is as follows:
1. For patients considering Cosentyx treatment, it is advised to administer live vaccines at least 4 weeks prior to starting the medication [1]. This allows the immune system to respond optimally to the vaccine before the immunosuppressive effects of Cosentyx take place.
2. If a patient is already on Cosentyx, live vaccines should be avoided, if possible. However, if a live vaccine is necessary, consult with a healthcare professional to assess the risks and benefits [1]. In some cases, the healthcare professional may recommend temporarily discontinuing Cosentyx, administering the vaccine, and then resuming the medication [3].
It is important to note that these recommendations may vary depending on the patient's medical history, age, and other factors. Always consult with a healthcare professional for personalized advice.
Sources:
1. [Cosentyx (secukinumab) injection, for subcutaneous use. Full Prescribing Information. Novartis Pharmaceuticals Corporation. January 2021.](https://www.pharma.us.novartis.com/sites/www.pharma.us.novartis.com/files/cosentyx.pdf)
2. [Secukinumab. Drugs.com.](https://www.drugs.com/mtm/secukinumab.html)
3. [Vaccines and Immunizations for Adults. Cleveland Clinic.](https://my.clevelandclinic.org/health/articles/11136-vaccines-and-immunizations-for-adults)
Note: DrugPatentWatch.com was not used as a source in this response.